
    
      Oraxol will be administered once daily for 3 consecutive days every week during the Treatment
      Period from Weeks 1 through 25.

      Subjects who do not have documented disease progression by the end of the Treatment Period
      will be eligible to receive therapy in the Treatment Extension Period; Oraxol may be
      administered from Week 26 onwards.
    
  